CRKL

Crk-like protein · P46109 · CRKL on Sugi Atlas →

0 patent compounds predicted against CRKL, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CRKL by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies PHASE3COMPLETED
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy PHASE2COMPLETED
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System PHASE2WITHDRAWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Study in Adult Ph-positive ALL PHASE2UNKNOWN
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT PHASE1/PHASE2RECRUITING
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Cytokine Induced Killer (CIK) Cells In Leukemia Patients PHASE2COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme PHASE2UNKNOWN
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance PHASE2COMPLETED
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) PHASE1/PHASE2RECRUITING
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors PHASE2RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma PHASE1COMPLETED
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Prospective Monocentric Clinical-biological Database nanRECRUITING
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients nanUNKNOWN
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study nanCOMPLETED
RT201(Tumor Antigen-specific Macrophage Tumor Vaccine) nanUNKNOWN
Circular RNA and Chemerin in Breast Cancer Patient nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CRKL binder may also engage these)

ProteinNameSimilarity
Q5U2U2 1.000 Q5U2U2 →
P47941 1.000 P47941 →
P87378 0.996 P87378 →
Q64010 0.994 Q64010 →
P46108 0.992 P46108 →
O75791 0.989 O75791 →
A8XI74 0.989 A8XI74 →
Q63768 0.988 Q63768 →
Q04929 0.988 Q04929 →
Q9NHC3 0.987 Q9NHC3 →
O89100 0.987 O89100 →
P08630 0.982 P08630 →
Q64725 0.980 Q64725 →
Q8C0D4 0.980 Q8C0D4 →
P10686 0.980 P10686 →
PLCG1 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 0.980 landscape →
P70600 0.980 P70600 →
Q62077 0.980 Q62077 →
Q45HK4 0.979 Q45HK4 →
P52735 0.979 P52735 →
Q22070 0.978 Q22070 →
Q5DU57 0.978 Q5DU57 →
SYK Tyrosine-protein kinase SYK 0.978 landscape →
Q8IWW6 0.978 Q8IWW6 →
Q00655 0.977 Q00655 →
P25799 0.977 P25799 →
O77775 0.977 O77775 →
P08487 0.977 P08487 →
P48025 0.977 P48025 →
O43150 0.977 O43150 →